Vardenafil hydrochloride 是口服具有活性的、高效的、选择性的磷酸二酯酶 5抑制剂。它对 PDE1 (180 nM)，PDE6 (11 nM)，PDE2，PDE3，PDE4 (>1000 nM) 具有选择性。它能够非竞争性地抑制环磷酸鸟苷水解，提高 cGMP 水平。它可用于勃起功能障碍的研究。

Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes

After 12 weeks of treatment, a dose-dependent (P = 0.02) improvement in erections was noted for the GAQ, with 57 and 72% of men taking 10 mg or 20 mg vardenafil, respectively, reporting improved erections, in contrast to 13% after taking placebo (P< 0.0001). For the erectile function domain, dose-dependent (P = 0.03) final scores for the 10- and 20-mg dose were 17.1 and 19.0 compared with 12.6 for placebo (P< 0.0001). Both vardenafil doses significantly enhanced the rates of successful penetration (P< 0.0001) and successful intercourse (P< 0.0001) compared with placebo. Vardenafil treatment was effective in increasing intercourse success rates at all levels of baseline ED severity, at each level of plasma HbA(1c), and for type 1 and 2 diabetes. Treatment-emergent adverse events were primarily mild to moderate headache (

Cas No.

224785-91-5

分子式

C23H33ClN6O4S

分子量

525.06

别名

盐酸伐地那非;伐地那非

储存和溶解度

DMSO:100 mg/mL (190.45 mM),Need ultrasonic
H2O:100 mg/mL (190.45 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years